Category: LensAR Inc.
LensAR secures another $8 million in an equity funding round in support of its laser-based cataract surgery systems.
Opthalmology devices maker LensAR secured $8 million in equity funding, according to an SEC filing dated July 31, 2014.
Florida medical device maker LensAR raises $10 million from 14 unnamed investors, regulatory filings show.
Orlando, Fla.-based cataract surgery technology company LensAR closed an equity funding round with $10 million raised from 14 investors, regulatory documents show.
The fundraising effort, launched in December, was closed yesterday and use of the proceeds was not described, outside of an estimated $370,000 listed in payments to individuals listed as "executive officers, directors or promoters" of the company.
Florida medical device maker LensAR touts the launch of a U.K. clinical trial evaluating its laser system in treatment of patients with presbyopia.
Orlando, Fla.-based LensAR Inc. announced the launch of a new U.K. clinical trial, evaluating the company's laser-based lens softening system in treatment of patients with presbyopia.
The study begins with enrollment of the 1st 30 patients and will expand to more sites by the end of the year, LensAR said.
Florida laser cataract surgery technology company LensAR touts $87 million raised through private equity and debt financing.
Orlando, Fla.-based medical device company LensAR Inc. touted $87 million in fundraising, mostly through a debt financing agreement, in support of its laser cataract surgery systems.
LensAR raised $27 million in private equity financing and secured up to $60 million in debt financing. The company plans to use the funds to advance commercialization worldwide and to advance development of its cataract surgery platform.
Florida opthalmology devices maker LensAR raises $2.3 million of a hoped-for $19.8 million in equity funding.
Orlando, Fla.-based LensAR has raised $2.3 million so far among 3 unnamed investors, hoping to hit $19.8 million in equity funding, according to documents filed with the SEC.
The fundraising round, launched at the start of the month, isn't independent of any other business transaction, the company noted.
The FDA grants 510(k) clearance to LensAR's laser surgery system for a type of incision made during cataract surgeries.
The laser cataract surgery market has another player, now that the FDA's cleared its laser surgery device for another type of incision used during cataract surgery procedures.
LensAR said it won 510(k) clearance from the FDA for its laser cataract surgery device for arcuate incisions to the edge of the cornea.
The FDA OKs LensAR's laser system for executing corneal incisions, giving the system full indications for all the critical components of laser cataract surgery.
Orlando, Fla.-based LensAR won additional FDA clearance for its next-generation LensAR laser system, gaining indication for performing corneal incisions during cataract surgery.
With the latest regulatory win the LensAR system is cleared for all critical aspects of laser cataract surgery, including lens fragmentation, anterior capsulotomy and corneal incisions, according to the press release.